Battery innovation and the next wave of orthopaedic implants

Ilika Plc

Orthopaedic procedures today restore quality of life for millions each year, but failure rates remain a pressing issue. Infection, loosening, or mechanical collapse often reveal themselves only when pain returns, by which point revision surgery is the only option. The next generation of implants is being built to change that timeline entirely. By embedding sensors capable of measuring pressure, movement, and temperature, these devices can provide surgeons with a real-time window into the health of the joint.

Yet the ability to collect and send this information rests on a problem many overlook: powering the device without compromising its structural integrity. Conventional batteries are too bulky or unreliable to integrate safely into implants. This is where miniature solid state batteries enter the conversation. Designed at millimetre scale, they can be embedded within a prosthetic without weakening it, while still delivering the performance needed to drive sensors and communications.

Ilika’s Stereax M300, for instance, has been designed to address exactly these constraints. With a rectangular footprint just a few millimetres across, it offers the compactness necessary for true miniaturisation. Despite its size, it is capable of producing the pulse currents required for both sensing and wireless transmission. Equally important is the ability to recharge quickly and wirelessly, which not only ensures the longevity of the implant but also supports patient compliance by making at-home charging feasible and convenient.

Ilika plc (LON:IKA) is a pioneer in solid state battery technology enabling solutions for applications in Industrial IoT, MedTech, Electric Vehicles and Consumer Electronics.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Ilika builds the manufacturing path for Goliath solid-state batteries

Ilika is building the manufacturing and licensing pathway needed to move its Goliath solid-state battery technology towards larger-scale commercial production.

Ilika: Stereax revenue growth and Goliath opportunities ahead

Morphose Capital Partners’ Dr Tom McColm discusses Ilika’s FY26 results, the outlook for Stereax commercial revenues, progress with Goliath and potential opportunities in automotive, defence and e-bikes.

Ilika CEO highlights Stereax revenue growth and Goliath defence interest

Ilika CEO Graeme Purdy discusses Stereax product revenue, planned M300 battery deliveries, Goliath 10Ah development, EV market trends and rising demand from the defence sector.

Ilika plc reaches a commercial turning point as new markets emerge for Stereax and Goliath (video)

Dr Tom McColm of Morphose Capital Partners explains why the company may be approaching an important commercial inflection point.

Ilika plc: Stereax Revenue Arrives as Goliath Draws Defence Interest (video)

Ilika plc CEO Graeme Purdy outlines how Stereax has started generating product-related revenue, why M300 battery deliveries remain on track and how Goliath’s 10Ah prototype is opening new opportunities in defence and sovereign battery supply.

Ilika builds commercial momentum across Stereax and Goliath batteries

Ilika Plc reports annual results for the year ended 30 April 2026, highlighting progress on its Stereax medical battery line and Goliath large-format batteries for EV, defence and consumer applications. The company began Stereax production and deliveries, shipped larger Goliath prototypes, secured further grant funding and raised £5 million post-period to accelerate commercialisation.

Search